Helpful resources
Published works
- Apseloff G, Pardo A, Shram M, et al. Limited oral abuse potential of cebranopadol, a novel potent analgesic, compared to tramadol and oxycodone in recreational opioid users. Presented at PAINWeek 2023
- Fam D, Pardo A, Hackworth J. Cebranopadol, a novel potent analgesic: Pooled analysis of clinical ppiatewithdrawal scales. Presented at PAINWeek 2022.
- Tzschentke TM, Linz K, Koch T, Christoph T. Cebranopadol: A novel first-in-class potent analgesic acting via NOP and opioid receptors. HandbExpPharmacol. 2019;254:367-398.
- Scholz A, Bothmer J, Kok M, Hoschen K, Daniels S. Cebranopadol: A novel, first-in-class, strong analgesic: Results from a randomized Phase IIaclinical trial in postoperative acute pain. Pain Physician. 2018;21(3):E193-E206.
- Christoph A, Eerdekens MH, Kok M, et al. Cebranopadol, a novel first-in-class analgesic drug candidate: first experience in patients with chronic low back pain in a randomized clinical trial. Pain. 2017;158(9):1813-1824.
- Bothmer J, Scholz A, Höschen K, Daniels S. Cebranopadol, A novel first-in-class analgesic: Results from a study in patients with moderate to severe pain following bunionectomy. Presented at PAINWeek 2016.
- Linz K, Christoph T, Tzschentke TM, et al. Cebranopadol: A novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist. J Pharmacol Exp Ther. 2014;349:535-548
